BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/7/2020 3:43:52 AM | Browse: 662 | Download: 1257
 |
Received |
|
2020-03-17 05:33 |
|
Peer-Review Started |
|
2020-03-15 04:42 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-04-22 18:57 |
|
Revised |
|
2020-05-02 12:06 |
|
Second Decision |
|
2020-06-05 08:10 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-06-07 03:53 |
|
Articles in Press |
|
2020-06-07 03:53 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-06-23 02:29 |
|
Typeset the Manuscript |
|
2020-07-03 09:51 |
|
Publish the Manuscript Online |
|
2020-07-07 03:43 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhu-Zeng Yin, Zhi-Ming Zhao, Wen-Bo Tang, Nan Jiang, Ke-Di Zhang, Yu-Yao Song, Yang Wang, Cheng-Gang Li, Yuan-Xing Gao and Rong Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| China Postdoctoral Science Foundation |
2015M582853 |
|
| Corresponding Author |
Rong Liu, MD, PhD, Professor, The Second Department of Hepatopancreatobiliary Surgery, The First Medical Center, Chinese People’s Liberation Army General Hospital, Fuxing Road, No. 28, Beijing 100853, China. liurong301@126.com |
| Key Words |
Nab-paclitaxel; Gemcitabine; Pancreatic ductal adenocarcinoma; Surgery; Adjuvant; Resectable |
| Core Tip |
Nab-paclitaxel plus gemcitabine (AG) has resulted in better survival and tumor response rates for advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) compared with gemcitabine (GEM) alone. However, its role in adjuvant therapy for resected PDAC remains unclear. We retrospectively reviewed our PDAC database for patients with primary resectable PDAC who treated with AG or GEM alone as postoperative adjuvant chemotherapy between January 2013 and December 2016. Our results suggested that AG significantly improved disease-free survival and overall survival of patients with resected PDAC. AG may be potential option for postoperative adjuvant chemotherapy of resectable PDAC. |
| Publish Date |
2020-07-07 03:43 |
| Citation |
Yin ZZ, Zhao ZM, Tang WB, Jiang N, Zhang KD, Song YY, Wang Y, Li CG, Gao YX, Liu R. Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China. World J Clin Cases 2020; 8(13): 2778-2786 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i13/2778.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i13.2778 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
